Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Direxion Daily CSI China Internet Bull 2X Shares (CWEB) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Direxion Daily CSI China Internet Bull 2X SharesTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Direxion Daily CSI China Internet Bull 2X Shares vs Inovio Pharmaceuticals Inc — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $24.55, while Inovio Pharmaceuticals Inc trades at $0.78 (market cap $76.09M). The key difference: Direxion Daily CSI China Internet Bull 2X Shares is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CWEBINO
Sector
Leveraged / InverseHealth
52-Week High
$60.13$2.87
52-Week Low
$17.70$0.66
Market Cap
$76.09M
Enterprise Value
$47.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Direxion Daily CSI China Internet Bull 2X Shares

CWEB trades at $25.53, up 1.67% today, with a bullish technical signal from moving averages. The stock shows strong momentum indicators but an overbought short-term RSI. A dividend of $0.09 is scheduled for June 2026, reflecting potential income return. Recent news highlights renewed interest in China growth stocks, which may benefit CWEB's positioning.

The outlook for CWEB is cautiously optimistic, driven by positive technical trends and sector sentiment. Key risks include reliance on China market dynamics and potential volatility. Investment opportunity lies in growth stock resurgence, but investors must weigh macroeconomic and regulatory uncertainties in the region.

Inovio Pharmaceuticals Inc

INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.

High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Direxion Daily CSI China Internet Bull 2X Shares

CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.

Read more on CWEB

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO